In recent months China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year. The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further enhanced the sector’s appeal. Just like AI, China’s science is real, the economics are compelling, and the pipeline is starting to deliver, making them a force to be reckoned with on the world stage.
- We believe Chinese companies will become an increasing force over the coming years, just like BYD is giving Tesla a run for its money.
MM is bullish towards the Hang Seng Tech and Biotech Sectors
